630 Patients Enrolled To Date; Enrollment Completion Now Expected in Q1 2025 with Top-line Results Anticipated in Q2 2025; Upon Potential Positive Phase 3 Data the Company Expects to Submit a New Drug Application (“NDA”) for D-PLEX100 under Fast Track and...Read more
Richland, WA, Dec. 23, 2024 (GLOBE NEWSWIRE) -- – Vivos Inc. (OTCQB: RDGL) proudly announces the initiation of its first human clinical trial for RadioGel® Precision Radionuclide Therapy™ in India. This milestone trial, which has commenced with the successful treatment of five...Read more
ARO-INHBE targets a known pathway that signals the body to store fat in adipose tissue In preclinical studies ARO-INHBE reduced body weight and fat mass with a novel mechanism of action that may better preserve lean muscle mass compared to currently approved obesity...Read more
ALISO VIEJO, Calif. / Dec 23, 2024 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the submission of its New Drug...Read more
New Drug Application (NDA) is based on pooled data from the pivotal Phase 2 TRUST-I and TRUST-II studies of taletrectinib that demonstrated durable responses and prolonged progression-free survival in patients with advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) If approved,...Read more
VALENCIA, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that the U.S. Food and Drug Administration (FDA) has...Read more
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Eli Lilly | 28.52 3.71 | $796.28 |
| ZIVO Bioscience | 21.00 1,909.09 | $22.10 |
| Regeneron Pharmaceuticals | 13.28 1.89 | $715.13 |
| Finch Therapeutics | 9.00 500.00 | $10.80 |
| Humana | 8.65 3.50 | $255.75 |
| Vertex Pharmaceuticals | 8.00 2.01 | $405.27 |
| UnitedHealth | 5.50 1.10 | $505.63 |
| Elevance Health | 4.93 1.35 | $370.89 |
| Cigna | 4.71 1.70 | $281.63 |
| argenx | 4.16 0.67 | $627.98 |
| United Therapeutics | 4.07 1.13 | $363.65 |
| Novo Nordisk | 3.75 4.41 | $88.75 |
| Mettler-Toledo | 3.65 0.30 | $1,234.39 |
| Ascendis Pharma | 3.32 2.43 | $139.70 |
| Verona Pharma | 3.26 7.76 | $45.28 |
| Biogen | 2.91 1.99 | $149.38 |
| Mesoblast | 2.86 19.55 | $17.49 |
| Intuitive Surgical | 2.79 0.53 | $527.22 |
| Company | Volume | Last Trade |
|---|---|---|
| RAPT Therapeutics | 339,722,819 | $1.69 |
| Tonix Pharmaceuticals | 179,677,396 | $0.40 |
| Helius Medical Technologies | 58,179,954 | $0.91 |
| Quantum-Si | 51,221,665 | $1.31 |
| GT Biopharma | 47,438,684 | $2.75 |
| Geron | 39,501,740 | $3.34 |
| Check-Cap | 38,518,425 | $2.03 |
| Walgreens Boots Alliance | 37,094,877 | $9.31 |
| Recursion | 36,699,241 | $6.99 |
| Vyome | 36,361,564 | $0.22 |
| Pfizer | 33,595,258 | $26.71 |
| Aptose Biosciences | 31,227,301 | $0.25 |
| Aethlon Medical | 30,150,586 | $0.55 |
| Applied Therapeutics | 26,070,582 | $0.82 |
| Therapeutic Solutions | 25,623,239 | $0.00 |
| Sangamo Therapeutics | 20,725,478 | $2.39 |
| Conduit Pharmaceuticals | 19,542,734 | $0.06 |
| Novo Nordisk | 18,640,086 | $88.75 |
| Reviva Pharmaceuticals | 17,647,191 | $1.64 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
